newsfilter
← Latest News
GlobeNewswire·

Palvella Therapeutics to Participate in the Stifel 2026 Healthcare Conference

  • Palvella Therapeutics (NASDAQ: PVLA) announced that its management team will present at the Stifel 2026 Healthcare Conference on Tuesday, November 10, 2026, at 9:20 a.m. ET.
  • A live webcast of the presentation will be available on the company's website at www.palvellatx.com, with an archived replay accessible for approximately 90 days.
  • Palvella is a clinical-stage biopharmaceutical company developing novel therapies for serious, rare skin diseases & vascular anomalies lacking FDA-approved treatments.
  • The company's pipeline utilizes its patented QTORIN™ platform, focusing initially on lifelong conditions such as microcystic lymphatic malformations, cutaneous venous malformations, & clinically significant angiokeratomas.
  • Palvella's lead candidate, QTORIN™ 3.9% rapamycin anhydrous gel, is being developed for microcystic lymphatic malformations, cutaneous venous malformations, & angiokeratomas.
  • Palvella's second candidate, QTORIN™ pitavastatin, is being developed for disseminated superficial actinic porokeratosis.
  • Both QTORIN™ rapamycin & QTORIN™ pitavastatin are for investigational use only & have not received FDA approval.
  • The press release includes forward-looking statements regarding clinical trial data timing, NDA approval expectations, regulatory milestones, commercial launch plans, & financial runway.
  • Actual results may differ materially from forward-looking statements due to risks including capital raising, clinical trial outcomes, regulatory approval, competition, & intellectual property protection.
  • Investor contact is Wes Kaupinen (Founder & CEO) & media contact is Marcy Nanus (Vice President, Investor Relations & Corporate Affairs).